Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency.

@article{Mejias2005ComparativeEO,
  title={Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency.},
  author={Asuncion Mejias and Susana Chavez-Bueno and Ana Mar{\'i}a R{\'i}os and M{\'o}nica Fonseca Aten and Brett Raynor and Estrella Peromingo and Perla Soni and Kurt D. Olsen and Peter A. Kiener and Ana M G{\'o}mez and Hasan S. Jafri and Octavio Ramilo},
  journal={Antimicrobial agents and chemotherapy},
  year={2005},
  volume={49 11},
  pages={4700-7}
}
Respiratory syncytial virus (RSV) is the leading viral pathogen responsible for bronchiolitis and pneumonia in infants and young children worldwide. We have previously shown in the mouse model that treatment with an anti-RSV neutralizing monoclonal antibody (MAb) against the F glycoprotein of RSV, palivizumab, decreased lung inflammation, airway obstruction, and postmethacholine airway hyperresponsiveness. MEDI-524, or Numax, is a new MAb derived from palivizumab with enhanced neutralizing… CONTINUE READING